Merrimack's Mulroy on Success of Pancreatic Drug Onivyde(Audio)
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. GUEST: Bob Mulroy, CEO of Merrimack Pharmaceuticals, on biotech earnings, consumer health and oncology, and its product pipeline. Broadcasting live from the Boston Convention and Exhibition Center.
See omnystudio.com/listener for privacy information.